Zenith Drugs (NSE SME)

User profile picture

Zenith Drugs (NSE SME)

February 19, 2024 – February 22, 2024

Price ₹75 - ₹79
Premium ₹35
Lot size 1600
Allotment Feb 23, 2024
Listing Feb 27, 2024

Login to view

Login

Live Rate

Open
High
Low
Prev. Close
Lower circuit
Upper circuit
52w High
52w Low
P/E Ratio

Subscription

Last updated on 22-Feb-2024 17:00:03

CategoryOfferedAppliedTimes
QIB85920091697600106.72
NIB644800238539200369.94
RETAIL1504000208404800138.57
Total3008000538641600179.07
Retail Apps130253© IPO Premium
HNI Interest Cost per share (7 Days)
@7%
₹39.23
@8%
₹44.84
@9%
₹50.44
@10%
₹56.05
@11%
₹61.65
@12%
₹67.26

About

Category Lot(s) Qty Amount Reserved
Retail 1 1600 126400 940
HNI 2 3200 252800 403

ANCHOR INVESTORS

Name of the Anchor InvestorNo. of Equity Shares allocated% of AnchorAmount Allocated (in Crores)
Vikasa India EIF I Fund – Zodiac Global Opportunity Fund2,11,20016.40%1.672
Chanakya Opportunities Fund I1,28,0009.94%1.011
Moneywise Financial Services Pvt. Ltd1,28,0009.94%1.011
Aries Opportunities Fund Limited2,52,80019.63%1.994
Neomile Growth Fund – Series I1,90,40014.78%1.506
Meru Investment Fund PCC – Cell 13,77,60029.32%2.989

Established in 2000, Zenith Drugs Limited stands as a distinguished pharmaceutical enterprise, dedicated to the production and distribution of top-tier, cost-effective medications, notably generic drugs.

Operating in strict accordance with WHO-GMP standards, the company has earned recognition for its unwavering dedication to quality, exemplified by its attainment of the ISO 9001:2015 certification from a reputable EuroUK certification authority.

Zenith Drugs Limited offers a diverse product line encompassing:

  1. ORS Powder
  2. Liquid Orals
  3. Ointments
Zenith Drugs IPO Details
Issue Size5,148,800 shares
(aggregating up to ₹40.68 Cr)
Fresh Issue5,148,800 shares
(aggregating up to ₹40.68 Cr)
Issue TypeBook Built Issue IPO
Listing AtNSE SME
Share holding pre issue12,000,000
Share holding post issue17,148,800
Market Maker portion852,800 shares (YES 852800)
Gretex Share Broking
Zenith Drugs IPO Reservation
Investor CategoryShares Offered
QIB Shares OfferedNot more than 16.69% of the Net Issue
Retail Shares OfferedNot less than 29.21% of the Net Issue
NII (HNI) Shares OfferedNot less than 12.52% of the Net Issue
Zenith Drugs IPO Lead Manager(s)
  • Gretex Corporate Services Limited
Key Performance Indicator

KPI

2023

2022

2021

ROE

35.13%

29.83%

40.73%

ROCE

37.29%

30.08%

36.52%

D/E Ratio

1.51

1.56

1.73

RONW

29.88%

25.96%

33.84%

Basic & Diluted EPS

4.29

2.62

2.52

P/E Ratio

18.4

-

-

P/BV Ratio

5.5

-

-

Strength Factors

Experienced Promoters and Management Team: The company benefits from seasoned promoters and a skilled management team, providing strong leadership and strategic direction.

Cost Efficiency: Emphasis on cost efficiency ensures optimal resource utilization, enhancing profitability and competitiveness.

Formulation & Development: Capabilities in formulation and development enable the company to innovate and adapt to changing market needs, fostering product differentiation and growth.

Regulatory Compliance: Adherence to regulatory requirements ensures legal and operational compliance, mitigating risks and enhancing reputation.

Global Reach: The company's global reach expands market opportunities and diversified revenue streams, reducing dependency on specific regions..

 

Risk Factors

Restrictive Financing Conditions: The company operates under restrictive conditions imposed by lenders, necessitating prior written consent for capital structure changes, amalgamation schemes, and borrowing arrangements. This could potentially limit the company's financial flexibility and operational agility from an external viewpoint.

Dependency on Raw Materials and Suppliers: Heavy reliance on major raw materials and a select group of suppliers, without long-term agreements, poses a risk. Inability to secure adequate raw materials at competitive prices may adversely affect the company's business operations and financial health, observed from an external standpoint.

Manufacturing and Quality Control Risks: Any lapses in manufacturing or quality control processes could disrupt operations, tarnish the company's reputation for excellence, and expose it to potential legal liabilities. This could have a detrimental impact on the company's business prospects, cash flows, and financial condition from an external observer's perspective.

Increased Competition: Inadequate response to heightened competition may result in loss of market share and declining profitability. This could negatively affect the company's business performance, operational outcomes, and financial standing as viewed externally.

Delays and Defaults in Customer Payments: Delays or defaults in customer payments could strain working capital and diminish profits, impacting the company's operational efficiency and financial stability from a third-party viewpoint.

Company Financials
Zenith Drugs Limited Financial Information (Restated Consolidated)

Zenith Drugs Limited's revenue increased by 24.85% and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023 and March 31, 2022.

Period30 Sep 2023Mar 2023Mar 2022
Assets11,249.049,793.836,858.47
Revenue6,948.4311,569.659,266.63
Profit539.38515.29312.86
Net Worth2,264.961,724.421,209.09
Reserves1,064.961,684.421,169.09
Borrowing2,902.812,605.031,880.86
Amount in ₹ Lakhs

Strength

Weakness

Address

Zenith Drugs Limited
K. No. 72 / 5, Village Muradpura
NA Depalpur,
Indore-453001
Phone: +91 8435501867
Email: info@zenithdrugs.com
Website: https://zenithdrugs.com/

Registrar

Bigshare Services Pvt Ltd
Address: Bigshare Services Pvt Ltd 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis,Makwana Road, Marol, Andheri(E), Mumbai - 400 059